We are pleased to announce the 14th Annual European Life Sciences CEO Forum, which will take place on the 10th - 12th of March 2021 and be part of the DigitalSachs Spring Life Sciences Week, that will also incorporate the 2nd Annual European HealthTech CEO Forum.
Due to the pandemic we have decided that for the first time Sachs Zurich events will be held in a digital format. This will allow us to support our community and past attendees. We will provide both the usual stimulating programme and the networking opportunities through the audio/video online meeting system.
Back for its 14th Annual Edition, this global bio-pharma industry event will address through its programme the main challenges for 2021 in investment, partnering and alliance management. Key players contribute their insights in panels which cover the macro picture as well as innovation in different therapeutic sectors.
The main programme for the 14th AnnualELSF is spread throughout 2 days (10th-11th of March) and will include BioCapital & Investment Day and Bio-Pharma Partnering & Therapeutics Day. The two days will feature more than 14 hours of high-level speeches, panel discussions and spotlight showcases by leading industry corporates. In addition, there is a global company showcase of 50+ presentations by established public, private, emerging and seed companies, offering innovative solutions and seeking investment and partnering opportunities. We anticipate 400+delegates will register for the forum from all Life Sciences sectors, with the target audience being corporate and financial investors/partners, bankers and advisors.
Meetings will take place from the 8th to 12th of March. Moreover, the system will be open for 12 hours a day and we expect 1500+ meetings completed over 5 days. The conference will be held in the Central European Time Zone. The digital event will consist of:
BioCapital & Investment Day (Wednesday, 10th of March)
State of the Industry Panel
China Partnering & Investment Panel
European Equities Investment Panel
Accessing US Capital Markets Panel
VC, Private Equity & Crossover Funds Panel
Early Stage Innovation & Investment Panel
Bio-Pharma Partnering & Therapeutics Day (Thursday, 11th of March)
Pharma M&A and Partnering Panel
Immuno-Oncology Partnering Panel
Advances in Immuno-Oncology Panel
Platform Technologies & Novel Therapeutics Panel
Genetic Medicine & New Modalities Panel
Progress in Alzheimer’s, Dementia & Diagnostics Panel
Networking Day (Friday, 12th of March)
Confirmed Keynote Speakers Include:
Kurt Höller, Director of Business Creation, EIT Health e.V.*
Big Pharma Fireside Chat with Nigel Sheail, Global Head of M&A and BD&L, Novartis International AG, moderated by Jeffrey Bockman, EVP, Head of Oncology Practice, Cello Health BioConsulting.
Introductory Speech by Sandra Ferri, Head of Life Sciences, European Investment Fund
Keynote: “How China is Transforming the Clinical Development Landscape & the Biopharma Industry” By John Oyler, Co-Founder, Chairman & CEO, BeiGene Ltd.
Confirmed Speakers Include:
Adam Kostyál, SVP of the Global Listing Services & Head of European Listings, Nasdaq
Andreas Hohn, Director of Transaction Excellence, Roche Partnering, F. Hoffmann-La Roche Ltd.
Anker Lundemose, CEO, Mission Therapeutics Ltd
Aram Mangasarian, CEO, NOXXON Pharma NV
Ashish Patel, Principal, Optum Ventures
Bibhash Mukhopadhyay, Principal, New Enterprise Associates (NEA)
Carlos de Sousa, CEO, Ultimovacs ASA
Carlos Buesa, Founder & CEO, Oryzon Genomics S.A.
Chris Maggos, Managing Director, Head of Europe, LifeSci Advisors
Christophe Bourrilly, Head of Healthcare, Oddo BHF co-chair for European Capital Markets Panel
Corinne Venot, Senior Director, Business Development, BeiGene Ltd.
Tim Haines, Chairman & Managing Partner, Abingworth
Tomas Landh, Innovation Sourcing VP, Senior Principal Scientist R&D Global Search & Evaluation, Novo Nordisk A/S
Wesley Holmes, Partner, Latham & Watkins LLP
Yochi Slonim, Co-Founder & CEO, Anima Biotech, Inc.
Zhihong Chen, President & CEO, Curon Biopharmaceutical
Free access to view live sessions is provided to all interested and qualified participants. This will allow us to increase the size of the audience and provide a higher exposure for participating companies. Additionally, you can purchase a Video on Demand pass, which will allow you to view not only live sessions, but also recordings of all sessions, in addition to speaker and company profiles and their presentations.
The Online Meeting System will open on the 22nd of February for uploading profiles and sending meeting invites. Meetings will take place from the 8th to 12th of March. System will allow you to have a secure audio/video call, as well as option to present slides using screen share function. Meetings will last for 30 minutes. Basic Online Meeting System Access with 10 meeting invitations will be provided complimentary for qualified institutional (buy/sell-side), private equity and venture investors. The number of passes is limited, and priority is given to regular participants, however organizer has the discretion to reject passes. Other participants may consider purchasing Basic, Advanced and Premium Access with an option for a live spotlight or a pre-recorded showcase presentation. The number of meeting invites defines how many requests can be sent. If meeting invite is declined, you will receive an invite credit back that can be reused. The number of invites does not restrict how many meeting invitations you can receive.
Gain additional exposure to high-level decision makers by presenting at the forum, which offers excellent opportunities to showcase your company’s investment and partnering offering. This typically include technology and financial highlights. This adds to the news flow from the forum and generates greater interest in meetings from other delegates.
For those interested to join the companies’ showcases, there is an option to purchase either a 10 or 20 minute presentation, which will be pre-recorded in advance and available to all registered attendees before, during and after the conference on the event’s portal. There are also a limited number of 20-min Spotlight presentations with additional branding to provide even higher exposure, which will be broadcasted live during the main programme after relevant panel discussion and available on demand afterwards. Start-up companies, which are looking for seed financing may also apply for a 5 or 10 minute showcase option. The Sachs team can assist with the pre-recording of the presentation or you can upload a video you already have. Interested viewers will be able to message or request a meeting with you using the Online Meeting System.
Make connections, engage in conversation, and exchange knowledge with key decision-makers eager to learn how your company can help them meet their goals and achieve their mission. Exhibiting at Sachs Spring Life Sciences Week is an effective way to gain leads, introduce new products and services, expand sales, and build relationships.
The virtual exhibition package includes a dedicated virtual page, where we can: upload your branded company’s profile and list ways to reach you; share video or images about services you provide; have files ready for download, if you wish to share any additional information with potential clients.
There are a limited number of sponsorship opportunities for the forum, which includes speaking, advertising and branding options. Sponsors typically include investment banks and funds, large pharma, technology companies and service providers, including Stock Exchanges, IR companies, CROs, international lawyers and consulting companies. Tailored packages are available upon request. You can view latest event’s sponsors here.
To learn more about presenting, exhibition or sponsorship opportunities, please contact us at SachsTeam@SachsForum.com or by phone + 44 (0)203 463 4890.
FINANCIAL, ADVISORY, INVESTORS ATTENDING:
3B Future Health Fund (formerly Helsinn Investment Fund) 3B Future Health Ventures Sarl (Helsinn Investment Fund) 3E Bioventures 4BIO Capital AbbVie Deutschland GmbH Co. KG AbbVie Ventures Abingworth LLP ACXIT Capital Management GmbH Additio Investment Group Advent Life Sciences aescuvest international GmbH Aglaia Oncology Funds Aisling Capital LLC ALSA Ventures Altitude Investment Management Andera Partners Aqua Partners LLC ARCH Venture Partners Arix Bioscience Plc. ARTO AG Asabys Partners Asklepios Advisors ATEM Capital LLC Atlas Advisors LLC AVANTECA Partners AG Bergmann zur Hausen & Cie. GmbH BERNINA BioInvest Ltd. Bioqube Ventures Bioscience Managers Biotech Alliances International, Inc. Biotechnology Business Institute Bootstrap Europe Boston Consulting Group Bpifrance Breslin AG BRESLIN AG & LSFA Bridge Valley Ventures LLP Brightlands Venture Partners B.V. Brock Capital Group LLC Brothers & Partners Europe Bryan, Garnier & Co. GmbH Capricorn Partners NV Cathay Capital Cederberg GmbH Claris Ventures Clave Capital Clavis Capital Ltd. coparion GmbH & Co. KG Crosswave Management, Inc. CTI Life Sciences Curam Capital Management LLP DeBere Capital Partners Debiopharm Innovation Fund S.A. Digital Networks Plc. S.r.l. Dorset Capital LLC Eaton Square EIT Health Investor Network European Investment Fund Ferghana Partners Forbion Forty51 Ventures Fraser Finance LLP Fund+ FutuRx Ltd. GCF Family Office Generation Life Science Fund Genextra S.p.A. Gilde Healthcare Partners Gimv NV Global Founders Capital GmbH Global Investment Bridge AG Global Neurohealth Ventures GLSV GmbH Good Health Capital LLC GreenSky Capital GrowthCube Partners LLC Guoqian VC Gurnet Point Capital H.C. Wainwright H.C. Wainwright & Co., LLC Hadean Ventures AS HBM Partners AG Health Passion Fund HealthCap High-Tech Gründerfonds Hillhouse Capital Hovione Capital, Sociedade de Capital de Risco, SA i&i Prague s r.o. i2020 Accelerator